hc010
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 27, 2024 (NCT06307925)
Timeline
Indications
Mechanism of action
- SARS-CoV-2INHIBITOR
SARS-CoV-2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07169552 | Phase 2 | Sep 15, 2025 | HC Biopharma Inc. |
| NCT06307925 | Phase 1 | Mar 27, 2024 | HC Biopharma Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HC Biopharma Inc. | For profit | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1